Arrowhead Pharmaceuticals Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

Arrowhead PharmaceuticalsDie Gewinne des Unternehmens sind mit einer durchschnittlichen jährlichen Rate von -53.8% zurückgegangen, während in der Branche Biotechs die Gewinne wachsen. Die Umsätze sind gewachsen mit einer durchschnittlichen Rate von 6% pro Jahr.

Wichtige Informationen

-53.8%

Wachstumsrate der Gewinne

-52.4%

EPS-Wachstumsrate

Biotechs Wachstum der Industrie	17.0%
Wachstumsrate der Einnahmen	6.0%
Eigenkapitalrendite	-161.5%
Netto-Marge	-2,741.4%
Nächste Ertragsaktualisierung	26 Nov 2024

Jüngste Aktualisierungen vergangener Leistungen

Recent updates

Some Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shareholders Look For Exit As Shares Take 27% Pounding

Apr 03

Arrowhead: RNAi Specialist Struggling To Show A Strong Hand (Rating Downgrade)

Mar 30

Shareholders May Be Wary Of Increasing Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation Package

Mar 08

Estimating The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Feb 19

Arrowhead Pharmaceuticals: A Leading Small-Cap Developer Of RNAi Therapy

Jan 21

Pinning Down Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) P/S Is Difficult Right Now

Dec 25

Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Debt In A Risky Way?

Sep 19

Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares Climb 25% But Its Business Is Yet to Catch Up

Apr 17

Shareholders May Be More Conservative With Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation For Now

Mar 10

A Look At The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Jan 24

We're Not Worried About Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Cash Burn

Oct 24

Arrowhead Pharmaceuticals: Emerging From The 'Data Desert' With A Flood Of Opportunities

Sep 12

Johnson & Johnson And Arrowhead Pharmaceuticals Could Have Big News Coming

Aug 23

Arrowhead seeks New Zealand regulator nod to start trial of ARO-MMP7 for lung disease

Aug 17

Arrowhead Pharmaceuticals: An RNAi Name To Know

Jul 28

Arrowhead Pharmaceuticals names internal officer as new COO

Jul 20

Arrowhead begins dosing in early-stage studies of 2 potential lung disease drugs

Jul 05

Aufschlüsselung der Einnahmen und Ausgaben

Wie Arrowhead Pharmaceuticals Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.

Gewinn- und Umsatzhistorie

NasdaqGS:ARWR Einnahmen, Ausgaben und Erträge (USD Millions)
Datum	Einnahmen	Umsatz	Allgemeine und Verwaltungskosten	F&E-Ausgaben
30 Jun 24	20	-539	121	446
31 Mar 24	35	-471	119	390
31 Dec 23	182	-297	113	368
30 Sep 23	241	-205	109	337
30 Jun 23	256	-181	117	320
31 Mar 23	273	-150	125	298
31 Dec 22	278	-155	135	301
30 Sep 22	243	-176	137	284
30 Jun 22	250	-154	141	269
31 Mar 22	263	-112	123	258
31 Dec 21	144	-183	104	228
30 Sep 21	138	-141	85	202
30 Jun 21	108	-126	64	178
31 Mar 21	89	-110	56	151
31 Dec 20	80	-103	55	137
30 Sep 20	88	-85	54	127
30 Jun 20	124	-24	52	105
31 Mar 20	139	10	46	91
31 Dec 19	164	53	35	84
30 Sep 19	169	68	27	81
30 Jun 19	137	46	25	72
31 Mar 19	95	10	23	66
31 Dec 18	47	-29	20	58
30 Sep 18	16	-54	19	53
30 Jun 18	14	-54	18	51
31 Mar 18	22	-44	16	51
31 Dec 17	31	-35	13	54
30 Sep 17	31	-34	20	49
30 Jun 17	23	-46	25	49
31 Mar 17	13	-60	32	46
31 Dec 16	4	-75	42	40
30 Sep 16	0	-82	25	61
30 Jun 16	0	-84	41	39
31 Mar 16	0	-81	40	37
31 Dec 15	0	-89	36	39
30 Sep 15	0	-92	35	47
30 Jun 15	0	-90	32	45
31 Mar 15	0	-85	30	44
31 Dec 14	0	-71	28	37
30 Sep 14	0	-59	25	23
30 Jun 14	0	-50	19	17
31 Mar 14	0	-44	16	13
31 Dec 13	0	-37	13	10

Qualität der Erträge: ARWR ist derzeit unrentabel.

Wachsende Gewinnspanne: ARWR ist derzeit unrentabel.

Analyse von freiem Cashflow und Gewinn

Analyse des Gewinnwachstums in der Vergangenheit

Ergebnisentwicklung: ARWR ist unrentabel, und die Verluste haben in den letzten 5 Jahren mit einer Rate von 53.8% pro Jahr zugenommen.

Beschleunigtes Wachstum: Das Gewinnwachstum des letzten Jahres kann nicht mit dem 5-Jahres-Durchschnitt von ARWR verglichen werden, da das Unternehmen derzeit nicht profitabel ist.

Erträge im Vergleich zur Industrie: ARWR ist unrentabel, was einen Vergleich des Gewinnwachstums des letzten Jahres mit der Branche Biotechs (16.6%) erschwert.

Eigenkapitalrendite

Hohe Eigenkapitalrendite: ARWR hat eine negative Eigenkapitalrendite (-161.48%), da es derzeit unrentabel ist.

Arrowhead Pharmaceuticals Vergangene Ertragsentwicklung

Vergangenheit Kriterienprüfungen 0/6

Wichtige Informationen

Jüngste Aktualisierungen vergangener Leistungen

Third quarter 2024 earnings released: US$1.38 loss per share (vs US$0.96 loss in 3Q 2023)

Second quarter 2024 earnings released: US$1.04 loss per share (vs US$0.46 profit in 2Q 2023)

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Full year 2023 earnings: EPS and revenues miss analyst expectations

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Recent updates

Arrowhead Pharmaceuticals, Inc. Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome

Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) A Risky Investment?

New major risk - Financial position

Consensus revenue estimates decrease by 14%

Arrowhead Pharmaceuticals, Inc. Presents New Pivotal Phase 3 Data At ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome

Consensus revenue estimates fall by 22%

Arrowhead Pharmaceuticals, Inc. to Advance Two New RNAi-Based Obesity Candidates, ARO-INHBE and ARO-ALK7, into Clinical Studies

Price target decreased by 7.5% to US$46.54

New minor risk - Financial position

Third quarter 2024 earnings released: US$1.38 loss per share (vs US$0.96 loss in 3Q 2023)

Arrowhead Pharmaceutical: Driving To Commercialization

Now 20% overvalued after recent price rise

Now 8.9% undervalued

Arrowhead Pharmaceuticals to Advance RNAi-Based Plozasiran into Phase 3 Capitan Cardiovascular Outcomes Trial

Now 26% overvalued

Now 21% overvalued

Estimating The Fair Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Arrowhead Pharmaceuticals, Inc. Reports Successful Topline Results for Plozasiran from the Pivotal Phase 3 Palisade Study in Patients with Familial Chylomicronemia Syndrome

Arrowhead Pharmaceuticals: Hoping Something Sticks

Arrowhead Pharmaceuticals Presents New Clinical Data Showing ARO-RAGE Achieves High Level of Gene Knockdown in Patients with Asthma

Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Too Much Debt?

Arrowhead Pharmaceuticals: Focus Turns To Upcoming Pipeline Inflection Point

Second quarter 2024 earnings released: US$1.04 loss per share (vs US$0.46 profit in 2Q 2023)

Now 24% undervalued after recent price drop

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease

Arrowhead Pharmaceuticals, Inc. Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo

Some Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shareholders Look For Exit As Shares Take 27% Pounding

Arrowhead: RNAi Specialist Struggling To Show A Strong Hand (Rating Downgrade)

Chief Financial Officer recently sold US$1.4m worth of stock

Chief Financial Officer notifies of intention to sell stock

Shareholders May Be Wary Of Increasing Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation Package

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy

Now 25% overvalued after recent price rise

Estimating The Intrinsic Value Of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Consensus revenue estimates decrease by 19%, EPS upgraded

First quarter 2024 earnings: EPS and revenues miss analyst expectations

CEO, President & Director notifies of intention to sell stock

Arrowhead Pharmaceuticals, Inc., Annual General Meeting, Mar 14, 2024

Arrowhead Pharmaceuticals, Inc. Announces Leaving of Javier San Martin, M.D., as the Chief Medical Officer, Effective from February 1, 2024

Arrowhead Pharmaceuticals: A Leading Small-Cap Developer Of RNAi Therapy

Insider notifies of intention to sell stock

Arrowhead Pharmaceuticals, Inc. has completed a Follow-on Equity Offering in the amount of $450.015 million.

CEO, President & Director notifies of intention to sell stock

Pinning Down Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) P/S Is Difficult Right Now

CEO, President & Director notifies of intention to sell stock

Price target decreased by 7.7% to US$52.23

Consensus revenue estimates fall by 10%

Full year 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Financial position

Arrowhead Pharmaceuticals, Inc. Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-DM1 for Type 1 Myotonic Dystrophy

New minor risk - Insider selling

Chief Medical Officer recently sold US$567k worth of stock

Chief Medical Officer notifies of intention to sell stock

Arrowhead Pharmaceuticals Inc. Presents New Phase 2 Data on Plozasiran and Zodasiran at AHA 2023

New major risk - Revenue and earnings growth

CEO, President & Director notifies of intention to sell stock

Is Arrowhead Pharmaceuticals (NASDAQ:ARWR) Using Debt In A Risky Way?

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Chief Financial Officer recently sold US$543k worth of stock

Chief Financial Officer notifies of intention to sell stock

Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate A Phase 1 Study of Aro-Sod1

Chairman of the Board recently sold US$266k worth of stock

Consensus revenue estimates increase by 44%

CEO, President & Director notifies of intention to sell stock

Forecast to breakeven in 2023

Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) Shares Climb 25% But Its Business Is Yet to Catch Up

Shareholders May Be More Conservative With Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) CEO Compensation For Now

Arrowhead Pharmaceuticals, Inc. Gains Full Rights to NASH Candidate ARO-PNPLA3 with Promising Phase 1 Results

Consensus revenue estimates fall by 26%